BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Haematologica
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma | 2 Minute Medicine
Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR | Leukemia
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Selinexor combined with bortezomib + dexamethasone: the BOSTON trial
VisualAbstract: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | 2 Minute Medicine
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
The Lancet on X: "NEW—First large randomised phase 3 trial (BOSTON) finds regimen of selinexor, bortezomib & dexamethasone was associated with significant increase in progression-free survival vs bortezomib & dexamethasone in patients
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial | Bone Marrow Transplantation
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
British Journal of Haematology | Wiley Online Library
British Journal of Haematology | Wiley Online Library
![PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c00c798d130ef4c229a76e469d1c8e224ebc765b/3-Table2-1.png "PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar")
PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised ...
Treatment indications of multiple myeloma VTD : Bortezomib -Thalidomide... | Download Scientific Diagram
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
![PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c00c798d130ef4c229a76e469d1c8e224ebc765b/4-Table5-1.png "PDF] Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Semantic Scholar")